Advanced Imaging for Prostate Cancer

Recruiting in Palo Alto (17 mi)

Overseen ByPeter Chung, MD

Age: 18+

Sex: Male

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University Health Network, Toronto

No Placebo Group

Trial Summary

What is the purpose of this trial?The integration of magnetic resonance imaging (MRI) in the treatment planning process for prostate cancer will reduce uncertainties in delineation of the prostate gland, and will enable delineation of the urethra, penile bulb, and internal pudendal artery. The integration of daily cone-beam computed tomography (CBCT) will markedly reduce set-up uncertainties, thereby reducing the minimum planning target volume (PTV) margin. By combining MRI simulation and daily CBCT, and by adapting radiation delivery accordingly, the investigators will reduce dose delivered to the rectum, bladder, urethra, and erectile structures. In this study, the investigators seek to determine whether this dose reduction translates to improved patient outcomes. In a prospective, 2-stage design, up to 190 patients will be enrolled. In the first stage, advanced imaging will be integrated without altering dose planning techniques. Stage 2 will reduce dose delivered to normal tissues, and will collect toxicity outcome measures. This clinical trial will be conducted over 3 years.

Eligibility Criteria

This trial is for men with low or intermediate risk localized prostate cancer, specifically those with a Gleason score of 7 or less, PSA under 20, and no more than half of biopsy cores involved with tumor. It's not for men who've had hip replacements, inflammatory bowel diseases, severe reactions to prostate biopsies, or are on certain anticoagulant therapies.

Inclusion Criteria

My prostate cancer is at an early stage, with a low Gleason score, PSA under 20, and limited tumor involvement.

Exclusion Criteria

I had a severe reaction to a previous prostate biopsy.

I refuse to have fiducial marker placement.

I am not receiving a specific prostate cancer radiation treatment of 78Gy in 39 doses.

I have inflammatory bowel disease or a connective tissue disorder.

I cannot safely stop my blood thinner medication.

Participant Groups

The study tests if using advanced MRI in planning and daily CBCT imaging during treatment can improve outcomes by reducing radiation doses to non-cancerous parts like the rectum and bladder. The trial has two stages: first integrating advanced imaging without changing dose plans; secondly reducing doses to healthy tissues.

1Treatment groups

Experimental Treatment

Group I: MRI + CBCT in prostate cancerExperimental Treatment1 Intervention